

## Lupin buys 3 trademarks from Boehringer Ingelheim to strengthen diabetes portfolio

17 December 2024 | News

**GIBTULIO®, GIBTULIO MET® and AJADUO® are key components for diabetes treatment**



Global pharma major Lupin has announced the acquisition of anti-diabetes trademarks GIBTULIO®, GIBTULIO MET® and AJADUO® from Boehringer Ingelheim International GmbH (Boehringer Ingelheim), to strengthen its diabetes portfolio in the country.

As per the terms of the agreement, the trademark rights for these brands will be transferred to Lupin by March next year. Lupin has been marketing GIBTULIO® and GIBTULIO MET® since 2016, and AJADUO® since 2018 in the Indian market through existing co-marketing agreements with Boehringer Ingelheim India.

GIBTULIO® (empagliflozin), GIBTULIO MET® (empagliflozin + metformin) and AJADUO® (empagliflozin + linagliptin) belong to a novel class of oral anti-diabetic drug, sodium glucose co-transporter-2 (SGLT-2) inhibitor (and combinations). These are indicated to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. Empagliflozin is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes, and the risk of cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease.

An estimated 80 million people above the age of 18 years have diabetes in India, in addition to 25 million that are pre-diabetic. Awareness of diabetes is low with more than 50% of people unaware of their diabetic status, leading to multiple health complications, if not detected and treated early. Adults with diabetes have an increased risk of heart attack and stroke.